← Evidence map

TrialClinical drug investigation2026

A Single-Center, Randomized, Open-Label, Two-Formulation, Two-Sequence, Two-Period Crossover Study to Evaluate the Bioequivalence of Two Eltrombopag Olamine Tablets (25 mg) in Healthy Chinese Subjects in the Fed State.

Keyi Wu et al.PubMed ↗Publisher ↗

No numbers read from the abstract.

Not cited yet

The trial

NCT0676861936 enrolled2023

A Single-Center, Randomized, Open-Label, Two-Formulation, Two-Sequence, Two-Period Crossover Study to Evaluate the Bioequivalence of Two Eltrombopag Olamine Tablets (25 mg) in Healthy Chinese Subjects in the Fed State. | OpenQuestion